| Immunobiological Characterization of Cancer Stem Cells Isolated from Glioblastoma PatientsImmune Properties of GBM-Derived Stem Cells T Di Tomaso, S Mazzoleni, E Wang, G Sovena, D Clavenna, A Franzin, ... Clinical Cancer Research 16 (3), 800-813, 2010 | 318 | 2010 |
| Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients. A Anichini, C Maccalli, R Mortarini, S Salvi, A Mazzocchi, P Squarcina, ... The Journal of experimental medicine 177 (4), 989-998, 1993 | 254 | 1993 |
| Novel technologies and emerging biomarkers for personalized cancer immunotherapy J Yuan, PS Hegde, R Clynes, PG Foukas, A Harari, TO Kleen, P Kvistborg, ... Journal for immunotherapy of cancer 4 (1), 1-25, 2016 | 219 | 2016 |
| Human NK cells selective targeting of colon cancer–initiating cells: a role for natural cytotoxicity receptors and MHC class I molecules R Tallerico, M Todaro, S Di Franco, C Maccalli, C Garofalo, R Sottile, ... The Journal of Immunology 190 (5), 2381-2390, 2013 | 208 | 2013 |
| Immunology and immunotherapy of colorectal cancer P Dalerba, C Maccalli, C Casati, C Castelli, G Parmiani Critical reviews in oncology/hematology 46 (1), 33-57, 2003 | 178 | 2003 |
| Defining the critical hurdles in cancer immunotherapy BA Fox, DJ Schendel, LH Butterfield, S Aamdal, JP Allison, PA Ascierto, ... Journal of translational medicine 9 (1), 1-15, 2011 | 172 | 2011 |
| Cytotoxic T cells directed to tumor antigens not expressed on normal melanocytes dominate HLA-A2. 1-restricted immune repertoire to melanoma. A Anichini, R Mortarini, C Maccalli, P Squarcina, K Fleischhauer, ... The Journal of Immunology 156 (1), 208-217, 1996 | 170 | 1996 |
| Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan … M Sensi, C Traversari, M Radrizzani, S Salvi, C Maccalli, R Mortarini, ... Proceedings of the National Academy of Sciences 92 (12), 5674-5678, 1995 | 135 | 1995 |
| Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study AM Di Giacomo, PA Ascierto, P Queirolo, L Pilla, R Ridolfi, M Santinami, ... Annals of Oncology 26 (4), 798-803, 2015 | 124 | 2015 |
| Expression of cytokine genes, including IL-6, in human malignant melanoma cell lines. MP Colombo, C Maccalli, S Mattei, C Melani, M Radrizzani, G Parmiani Melanoma research 2 (3), 181-189, 1992 | 121 | 1992 |
| Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis W Hendrickx, I Simeone, S Anjum, Y Mokrab, F Bertucci, P Finetti, ... Oncoimmunology 6 (2), e1253654, 2017 | 116 | 2017 |
| Immunology of cancer stem cells in solid tumours. A review C Maccalli, A Volontè, C Cimminiello, G Parmiani European journal of cancer 50 (3), 649-655, 2014 | 114 | 2014 |
| Recommendations from the iSBTc-SITC/FDA/NCI workshop on immunotherapy biomarkers LH Butterfield, AK Palucka, CM Britten, MV Dhodapkar, L Håkansson, ... Clinical Cancer Research 17 (10), 3064-3076, 2011 | 114 | 2011 |
| Immunogenomic classification of colorectal cancer and therapeutic implications J Roelands, PJK Kuppen, L Vermeulen, C Maccalli, J Decock, E Wang, ... International journal of molecular sciences 18 (10), 2229, 2017 | 103 | 2017 |
| T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain … M Sensi, S Salvi, C Castelli, C Maccalli, A Mazzocchi, R Mortarini, ... The Journal of experimental medicine 178 (4), 1231-1246, 1993 | 101 | 1993 |
| Cancer-initiating cells from colorectal cancer patients escape from T cell–mediated immunosurveillance in vitro through membrane-bound IL-4 A Volonté, T Di Tomaso, M Spinelli, M Todaro, F Sanvito, L Albarello, ... The Journal of Immunology 192 (1), 523-532, 2014 | 100 | 2014 |
| Immunomodulating and immunoresistance properties of cancer-initiating cells: implications for the clinical success of immunotherapy C Maccalli, G Parmiani, S Ferrone Immunological investigations 46 (3), 221-238, 2017 | 81 | 2017 |
| NKG2D engagement of colorectal cancer‐specific T cells strengthens TCR‐mediated antigen stimulation and elicits TCR independent anti‐tumor activity C Maccalli, D Pende, C Castelli, MC Mingari, PF Robbins, G Parmiani European journal of immunology 33 (7), 2033-2043, 2003 | 77 | 2003 |
| Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine. M Sensi, C Farina, C Maccalli, R Lupetti, G Nicolini, A Anichini, ... The Journal of clinical investigation 99 (4), 710-717, 1997 | 74 | 1997 |
| TNK cells (NKG2D+ CD8+ or CD4+ T lymphocytes) in the control of human tumors C Maccalli, S Scaramuzza, G Parmiani Cancer immunology, immunotherapy 58 (5), 801-808, 2009 | 69 | 2009 |
Andrea AnichiniFondazione IRCCS Istituto Nazionale dei Tumori, Milanistitutotumori.mi.it의 이메일 확인됨
